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Effect of Calcium-Channel Blockade on the 
Aldosterone Response to Sodium Depletion 
and Potassium Loading in Man 
Laurent Favre, Anne Riondel, and Michel B. Vallotton 
Angiotensin H (Ang II) and potassium (K+) increase 
aldosterone (Aldo) production in vitro via Ca1*-dependent 
mechanisms. To determine the effects of Ca2+ antagonism 
in vivo, we examined the influence of nifedipine on the 
Aldo response to Na+ depletion and K+ loading in 11 
healthy subjects. On the fifth day of a low-Na+/high-K+ 
diet (10 mmol Na+/100 mmol K+) the subjects were 
randomly given either nifedipine 30 mg po or placebo, 
and on the sixth day they received the alternative drug. 
KCl in 5% glucose was infused on days 5 and 6 from 
10:00 to 12:00 AM(0.6 mmol/kg over 2 hours). Dexa-
methasone was given to suppress adrenal corticotrophic 
hormone. Plasma renin activity (PRA) and plasma Aldo 
were determined every 20 minutes. Nifedipine induced a 
rise in heart rate at 60 minutes but did not change blood 
pressure. During KCl/glucose infusions, plasma glucose 
increased significantly, but plasma K+ remained stable. 
PRA, but not baseline plasma Aldo, was stimulated by 
nifedipine. KCl provoked a significant and similar Aldo 
rise (P < .01) under placebo and nifedipine. Baseline 
Aldo/PRA ratio was reduced under nifedipine when 
compared to placebo (P < .01), whereas during KCl 
infusions this ratio was similarly elevated under placebo 
and nifedipine. We conclude that acute inhibition of slow 
Ca2+ channels does not interfere with K+-induced Aldo 
secretion in man, suggesting that adaptive mechanisms 
operate in vivo. Am J Hypertens 1988;1 :245-248 
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Potassium (K + ) and angiotensin II (Ang II) stimu­late aldosterone (Aldo) production via calcium (Ca 2 +)-dependent mechanisms. Earlier studies using isolated adrenal glomerulosa cells have 
shown that inhibition of C a 2 + uptake blocked the steroi­
dogenic response to both K + and Ang I I . 1 " 3 Recent work 
from this laboratory4 indicates that both Ang II and K + 
increase intracellular C a 2 + ( [Ca 2 + ] i ) , but they do so by 
different mechanisms: Whereas C a 2 + antagonists can 
From the Division of Endocrinology, University Hospital, Geneva, 
Switzerland. 
This study was supported by a grant from the Swiss National 
Science Foundation No. 3. 914-0 . 83. 
Address correspondence and reprint requests to Michael B. Vallot­
ton, Division of Endocrinology, University Hospital, CH-1211 Ge­
neva 4/Switzerland. 
totally block the K+-induced [Ca 2 + ] i rise resulting from 
the opening of voltage-dependent C a 2 + channels and 
the subsequent Aldo production, they do not suppress 
the receptor-mediated [Ca 2 + ] i rise induced by Ang II, 
though they reduce the steroidogenesis slightly. 
An inhibition of Aldo response to Ang II by acute 
administration of Ca 2 +-antagonists has been observed 
in human studies, 5" 7 but the effect of calcium antago­
nism on K+-induced Aldo stimulation has not yet been 
examined. The present study was therefore designed to 
compare the influence of nifedipine on the Aldo re­
sponse to N a + depletion and K + loading in normal man. 
The experimental protocol we used raised a further 
working hypothesis regarding the mechanism by which 
K+-induced Aldo stimulation may involve insulin ac­
tion. Our results suggest that intracellular K + may also 
influence Aldo secretion via a Ca 2 +-independent mech­
anism. 
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Eleven healthy male subjects aged 23 to 27 years volun­
teered to participate in the study. They gave their in­
formed consent to the experimental protocol, which has 
been approved by the Ethical Committee of the Depart­
ment of Medicine. 
The subjects were kept for 6 days on a strict low-Na + 
(15 mmol) and high-K + (100 mmol) daily intake. On 
day 5 the subjects were randomly given either nifedi­
pine (20 mg at 7:00 AM and 10 mg at 10:00 AM po) or a 
placebo. On day 6 they received the alternative drug. 
Dexamethasone (1 mg) was taken at midnight on days 4 
and 5 to suppress adrenal corticotrophic hormone 
(ACTH). On the fifth and the sixth days two similar 
KCl-infusion tests were performed from 10:00 AM to 
12:00 noon. After fasting overnight, the subjects re­
mained supine from 7:00 AM to 12:00 noon. KCl diluted 
in 5% glucose (50 mmol KC1/L) was infused over 2 
hours (0.6 mmol/kg) through a large humeral vein. 
Blood was drawn every 20 minutes during the KCl 
infusion for determination of plasma N a + and K + , 
plasma renin activity (PRA) and Aldo. Plasma glucose 
and plasma Cortisol were measured at 60 and 120 min­
utes. Plasma insulin was also determined in five sub­
jects. Blood pressure and heart rate were checked regu­
larly during the tests. Urinary N a + and K + were 
measured in 24-hour urine on the fifth day of the diet 
and in a urine spot on the sixth day. 
N a + and K + were determined by flame photometry 
and plasma glucose by the glucose-oxydase method. 
PRA, plasma Cortisol and insulin, and urinary Aldo were 
determined by radioimmunoassay (RIA). Plasma aldos­
terone was measured by RIA using a commercial kit 
(Coat-A-Count-Diagnostic Products Corp). The limit of 
detection was 1.5 ng /100 mL, and the intra-assay coef­
ficient of variation was 5 .1%. 
Statistical analysis was performed by paired t test, the 
subjects being their own controls. Results are expressed 
as the mean ± SEM. 
R E S U L T S 
On the fifth day of low-Na + /high-K + diet, 24-hour uri­
nary excretion was 19.8 ± 2.1 mmol for N a + and 
109.9 ± 9.0 mmol for K + . Urinary excretion of Aldo was 
42.0 ± 2 . 7 / /g /24 hours. In the sixth day urine spot N a + 
was 12.0 ± 2.2 mmol/L and K + , 77.0 ± 2.7 mmol/L. 
Mean body weight was 68.7 ± 3.3 kg on the fifth day 
and 68.5 ± 3.2 kg on the sixth day (difference not sig­
nificant [NS]). 
Before KCl infusion blood pressure was 114 ± 2 / 
69 ± 2 mm Hg on placebo and 115 ± 2 / 6 9 ± 1 mm Hg 
on nifedipine (NS). Heart rate was 61 ± 2 and 66 ± 3 
beats/minute, respectively (NS). At the end of the KCl 
infusion, blood pressure was 1 1 3 ± 2 / 7 1 ± 2 mm Hg 
on placebo and 115 ± 2 / 6 9 ± 2 mm Hg on nifedipine 
(NS), and heart rate was 60 ± 2 and 65 ± 3 beats/min-
ute, respectively (NS). However at 60 minutes, heart 
rate was significantly higher on nifedipine (75 ± 4) than 
on placebo (60 ± 2, Ρ < .01). 
The mean amount of KCl infused over 2 hours 
(0.6 mmol/kg) was 41.1 ± 1 . 7 mmol. Despite this large 
load, plasma K + did not change significantly during the 
2-hour infusion in either test (Figure 1). Plasma Na + 
remained constant. The infused volume was 831 ± 
42 mL over 2 hours, providing a glucose load of 41.6 ± 
2.1 g. On both placebo and nifedipine days, plasma glu­
cose and plasma insulin increased significantly to a 
similar extent during K C l - 5 % glucose infusion with a 
peak at 60 minutes. 
As shown in Figure 1, baseline PRA increased by Na + 
depletion was further stimulated by nifedipine treat­
ment, whereas plasma Aldo levels were similar on pla­
cebo and nifedipine days. Consequently the Aldo/PRA 
ratio was significantly higher on placebo (5.6 ± 0.6 at 
time 0) than on nifedipine (3.9 ± 0.5, Ρ < .01). During 
KCl infusion, despite the absence of change in plasma 
K + concentration, there was a marked and highly signif­
icant rise in plasma Aldo, reaching a peak at 40 minutes 
on placebo (P < .01 vs baseline) and at 60 minutes on 
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FIGURE 1. Effect of a 2-hour KCl IV infusion (0.6 mmol/kg in 
5% glucose) on plasma potassium concentration, plasma renin 
activity and plasma aldosterone levels, in 11 healthy subjects 
during sodium restriction. See text for statistics. 
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nifedipine (P < .001 vs baseline); peak values were not 
significantly different on placebo day (41.2 ± 10.0 ng/ 
dL) and on nifedipine day (34.8 ± 3.8 ng/dL). The 
Aldo/PRA ratio during KCl infusion was not signifi­
cantly different on placebo and on nifedipine. Plasma 
Cortisol levels remained suppressed during the tests 
(1.7 ± 0.4 /zg/dL on placebo and 1.3 ± 0.3 on nifedi-
pine/NS). 
D I S C U S S I O N 
In vitro studies using adrenal glomerulosa cells indicate 
that although Ang II and K + both stimulate Aldo secre­
tion by increasing [Ca 2 - 1^, only the K+-mediated stimula­
tion, acting through voltage-dependent C a 2 + channels, 
is specifically blocked by C a 2 + antagonists.4 Slow C a 2 + -
channel blockers can also decrease Ang II-induced 
Aldo production, but their effect is less marked than on 
KCl-induced steroidogenesis. This lesser effect is a con­
sequence of a lower basal intracellular C a 2 + concentra­
tion resulting from depletion of [Ca 2 + ] i stores by these 
drugs and preventing attainment of the critical thresh­
old for triggering steroidogenesis. From these in vitro 
findings, it might therefore be inferred that acute inhibi­
tion of C a 2 + channels would interfere with K+-induced 
Aldo stimulation. In a sheep whose adrenal gland was 
transplanted to its neck, the local infusion of C a 2 + antag­
onists reversed the Aldo response to K + but did not 
affect Aldo secretion induced by N a + depletion.8'9 
To assess the effect of K + on Aldo secretion, KCl 
was infused acutely after stimulation of the renin-
angiotensin system as in previous studies. 1 0 , 1 1 It is 
known that in normal subjects a clear Aldo response to 
K + occurs only in the presence of high concentrations of 
Ang II . 1 0 This fact emphasizes the important interde­
pendence of Ang II and K + . 1 2 KCl was diluted in glucose 
to prevent a local venous toxic reaction. Although 
plasma K + did not rise during the KCl-glucose infusion, 
there is strong evidence that Aldo stimulation was di­
rectly induced by K + , as previously reported. 1 0 Glucose 
ingestion acutely lowers plasma concentrations of K + 
and Aldo, 1 1 whereas plasma Aldo levels rise during 
KCl - glucose infusion, despite an unchanged K + plasma 
concentration,10 as confirmed in the present study. 
Whether K + enters the cell in order to stimulate steroi­
dogenesis is still conjectural, as opposite conclusions 
have been drawn from in vitro or in vivo studies using 
direct or indirect estimation of intracellular K + con­
tent . 1 0 1 1 , 1 3 Insulin stimulates K + cellular uptake by the 
liver and muscle tissues,14 but it is not known whether 
tissues like the adrenal cortex are also involved. These 
findings suggest that either membrane depolarization 
occurs without any apparent change in K + extracellular 
concentration (which is unlikely, as high concentration 
is required in vitro to depolarize glomerulosa cells 4), or 
that the signal may result from transmembrane K + 
fluxes leading to a higher intracellular K + concentration. 
If these processes are mediated by the C a 2 + fluxes dem­
onstrated in vitro,4 they would also be blocked in vivo 
by C a 2 + antagonists. This was not the case in this study 
because, contrary to our expectation, nifedipine was un­
able to prevent the K+-induced rise in Aldo concentra­
tion, the peak value of which during KCl infusion being 
similar on placebo and nifedipine treatment. Similar re­
sults showing no interference by nifedipine with Aldo 
secretion have been reported recently in hypertensive 
patients given an acute KCl infusion.1 5 Our findings 
indicate that the mechanism of K+-induced Aldo secre­
tion under these particular in vivo circumstances differs 
from that observed in vitro in isolated cells. In this study, 
as in an earlier one, 1 6 insulin response to hyperglycemia 
was not altered by nifedipine. The two KCl infusions 
were therefore comparable in terms of glucose load and 
insulin secretion. Insulin alone can influence plasma K + 
concentration, baseline plasma Aldo levels and its re­
sponse to Ang II in various ways. 1 7 
In the present in vivo human study under low salt 
intake, nifedipine reduced the Aldo/PRA ratio but did 
not alter K+-induced Aldo secretion. Renin secretion 
was clearly stimulated as a result of a combined effect of 
N a + depletion and acute inhibition of slow C a 2 + chan­
nels, and as previously reported, 1 8 it was not modified 
by KCl administration. The high basal plasma concen­
tration of Aldo induced by Ang II stimulation was simi­
lar on nifedipine and placebo. Despite the known higher 
sensitivity of adrenal cells after N a + depletion, 1 9 no fur­
ther increase in Aldo secretion could be obtained in re­
sponse to the acute renin rise under nifedipine treat­
ment. The finding of a lower Aldo/PRA ratio during 
nifedipine treatment, previously reported in hyperten­
sive patients, 2 0 is compatible with the acute inhibitory 
effect of nifedipine on steroidogenesis during Ang II 
infusion in man. 5 " 7 Another unrelated C a 2 + antagonist, 
verapamil, did inhibit Aldo response to Ang II, but only 
when given chronically. 2 1 During sodium restriction in 
normal subjects nifedipine and diltiazem reduced the 
sensitivity of Aldo secretion to Ang II . 7 
As nifedipine has been shown to increase apparent 
liver blood flow in normal subjects, 2 2 an alteration of 
Aldo metabolic clearance rate is to be considered so that 
changes in Aldo plasma concentrations may not parallel 
changes in Aldo secretion. To exclude any contribution 
of another Ca 2 +-independent adrenal trophic factor, 
ACTH was constantly suppressed by dexamethasone 
during the two test days. In fact Guthrie et a l 2 1 have 
reported that verapamil does not alter the Aldo response 
to ACTH. Nifedipine, known to bind with high affinity 
and specificity to the voltage-dependent C a 2 + chan­
nel, 2 3 was administered shortly before KCl infusion. It 
may be inferred from pharmacokinetic data that the 
dose selected would result in plasma concentrations in 
the same micromolar range as the in vitro studies, al­
though individual bioavailability may vary. 2 4 The PRA 
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rise obtained in every subject indicates that effective 
drug levels were achieved. Blood pressure was not in-
fluenced, as would be expected in normotensive sub-
jects. 2 5 
In summary, acute blockade of slow Ca 2 +-channels 
does not interfere with K +-induced Aldo secretion but 
reduces the Aldo/PRA ratio. These findings suggest 
some inhibition of the Ang 2-induced Aldo secretion. 
The discrepancy with in vitro findings indicates that 
adaptive mechanisms operate in vivo allowing the 
maintenance of Aldo secretion in normal man. Finally, 
these results support the existence of a role for intracel-
lular K + in stimulating Aldo secretion. 
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